U10 Ful Member Application Affiliated with SWOG

描述(由申请人提供)：德克萨斯大学安德森癌症中心(MDACC)于2002年11月作为正式成员加入西南肿瘤学小组(SWOG)。这是我们的第一个U10会员申请。在过去的3年里，完全在成为SWOG正式成员之前，MDACC平均每年有51项SWOG治疗研究的应计收益。我们的SWOG计划将整合MDAC综合多学科资源的许多要素，包括16个专门护理中心，在这些中心，大多数MDACC患者作为门诊患者以多学科、多模式的团队方法进行治疗。MDACC拥有895名癌症研究教员，其中包括536名临床教员。2001年，MDACC治疗了62,600名癌症患者，其中16,144人是新诊断的，3,500人参加了治疗方案。SWOG研究的协调结构包括首席调查员、联合首席调查员、CRA负责人、SWOG项目指导委员会和每个疾病现场项目的负责人(内科肿瘤学家、放射治疗师、外科医生)。每一位MDACC-SWOG计划病点负责人都是MDACC部门主席，由Waun Ki Hong博士领导，他是MDACC癌症医学部执行委员会的主席，他热情地支持MDACC内的SWOG治疗/应计活动。在过去的6年里，MDACC对SWOG做出了大量的行政贡献，包括癌症控制研究委员会主席和SWOG执行委员会/科学咨询委员会成员(李普曼博士)；胃肠委员会主席 下列组织的代表出席了会议：脑委员会联合主席(AbBruzzese博士)；脑委员会联合主席(Sawaya博士)；肺发育治疗委员会副主席(Herbst博士)；睾丸小组委员会主席(Logothetis博士)；肉瘤(特殊人群)委员会副主席(Bleyer博士)。至少有21名MDACC教职员工是SWOG的正式成员，并定期为SWOG的几个委员会(如胃肠委员会、脑委员会、肺委员会、H&N委员会和肉瘤委员会)做出积极贡献。Ei-Naggar博士将领导SWOG H&N肿瘤生物学和相关科学小组委员会。P.Pisters博士是SWOG肉瘤标本委员会的顾问。至少有11名MDACC教职员工在17个SWOG协调方案(包括3个开发方案)中作为研究协调员提供了科学领导，并共同撰写了18篇SWOG论文(自2000年以来)。MDACC将运用其历史优势，在SWOG环境下开发创新的第一、第二阶段研究。第三阶段试验非常复杂，任何单一机构都很难单独进行，MDACC期待着领导一些机构并加入SWOG的其他努力，在第三阶段，改变护理标准的试验中测试新的方法。

DESCRIPTION (provided by applicant): The UT M. D. Anderson Cancer Center (MDACC) joined the Southwest Oncology Group (SWOG) as a full member in November 2002. This is our first U10 member application. During the past 3 years and entirely prior to becoming a full SWOG member, MDACC averaged 51 accruals to SWOG therapy studies per year. Our SWOG Program will integrate many elements of MDACCs comprehensive multidisciplinary resources, including 16 specialized Care Centers, where most MDACC patients are treated as outpatients in a multidisciplinary, multimodality team approach. MDACC has 895 cancer research faculty, including 536 clinical faculty. In 2001, MDACC cared for 62,600 cancer patients, of whom 16,144 were newly diagnosed and 3,500 were enrolled in therapeutic protocols. The structure for coordinating SWOG studies includes the Principal Investigator, Co-Principal Investigator, Head CRA, SWOG Program Steering Committee, and leaders of each disease-site program (medical oncologists, radiotherapists, surgeons). Every MDACC-SWOG Program disease-site leader is a MDACC department chair sitting on the Executive Council of the Division of Cancer Medicine headed by Dr. Waun Ki Hong, who enthusiastically supports SWOG therapy/accrual activities within MDACC. Substantial MDACC administrative contributions to SWOG in the past 6 years include Chair, Cancer Control Research Committee and member, SWOG Executive Committee/Scientific Advisory Board (Dr. Lippman); Chair, Gastrointestinal Committee (Dr. Abbruzzese); Co-Chair, Brain Committee (Dr. Sawaya); Vice Chair, Lung Developmental Therapeutics Committee (Dr. Herbst); Chair, Testis Subcommittee (Dr. Logothetis); and Vice Chair, Sarcoma (Special Populations) Committee (Dr. Bleyer). At least 21 MDACC faculty are official members of SWOG and contribute actively to several SWOG committees on a regular basis (e.g., the Gastrointestinal, Brain, Lung, H & N, and Sarcoma committees). Dr. EI-Naggar will head the SWOG H&N Tumor Biology and Correlative Science Subcommittee. Dr. P. Pisters is a consultant for the SWOG Sarcoma Specimen Board. At least 11 MDACC faculty provided scientific leadership as Study Coordinators in 17 SWOG-coordinated protocols (including 3 in development) and co-authored 18 SWOG papers (since 2000). MDACC will apply its historical strengths in developing innovative Phase I, II studies within the SWOG setting. Phase III trials are highly complex and difficult for any single institution to conduct alone, and MDACC looks forward to leading some and joining other SWOG efforts to test novel approaches in Phase Ill, standard-of-care-altering trials.